SEC Filing Summary: Camp Nine, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Camp Nine, Inc. (not Relmada Therapeutics, Inc.) on June 2, 2014, reporting an event that occurred on May 30, 2014. The company is incorporated in Nevada and maintains its principal executive offices in New York, NY.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance action regarding capital structure authority.
Material Changes
On May 30, 2014, the Company amended its Articles of Incorporation to increase the aggregate number of authorized shares to 700,000,000. The breakdown of authorized shares is as follows:
- Common Stock: 500,000,000 shares (par value $0.001 per share).
- Preferred Stock: 200,000,000 shares (par value $0.001 per share).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the amendment of the Articles of Incorporation.
Investor Verification Checklist
- Verify the current ticker symbol and corporate name, as the input metadata referenced "Relmada Therapeutics, Inc." while the filing is for "Camp Nine, Inc."
- Confirm the number of shares currently outstanding versus the newly authorized 700,000,000 shares to assess potential dilution.
- Review the Nevada Certificate of Amendment (Exhibit 3.1) for any specific conditions attached to the preferred stock authorization.